Background. Glioblastoma (GBM) patients have an estimated survival of ~15 months with 35 treatment, and the standard of care only modestly enhances patient survival. Identifying 36 biomarkers representing vulnerabilities may allow for selection of efficacious chemotherapy 37 options to address personalized variations in GBM tumors. Irinotecan, currently in clinical trials 38 for GBM, targets topoisomerase I (TOP1) by forming a ternary DNA-TOP1 cleavage complex 39 (TOP1cc) inducing apoptosis. Tyrosyl-DNA phosphodiesterase 1 (TDP1) is a crucial repair 40 enzyme that may reduce the effectiveness of irinotecan. 41 42 3 Methods. We treated GBM cell lines with increasing concentrations of irinotecan and compared 43 the IC50 values. TOP1 and TDP1 protein levels from each cell type as well as GBM patient tumors 44 were determined by Western blot analysis, while activity levels were ascertained by specific 45 enzymatic assays. Cellular TDP1 was elevated by ectopic expression of wild-type or mutant TDP1. 46 47 Results. After comparing cellular susceptibility to TDP1 and TOP1 concentrations and activities, 48
Introduction 80
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults with a 81 dismal prognosis indicated by a 14.6-month median survival after surgical resection, radiotherapy, 82 and chemotherapy treatment with temozolomide (TMZ). 1 Irinotecan is used to treat metastatic 83 colorectal cancer and small cell lung cancer (SCLC). 2,3 Irinotecan has some capacity to cross the 84 blood-brain barrier, 4 and was shown to be effective against recurrent malignant glioma in early 85 phase II clinical trials. 5, 6 However, other clinical trials could not confirm the activity from 86 irinotecan monotherapy. 7, 8 Studies of irinotecan in combination therapy have yielded modest 87 activity as well. 7, [9] [10] [11] These seemingly discrepant results may indicate an underlying variability in 88 the susceptibility of patients in each trial towards the genotoxic chemotherapy. Thus, to improve 89 clinical outcomes and minimize toxic side-effects, identifying biomarkers for GBM susceptibility 90 to irinotecan would be instrumental for selecting patients for irinotecan treatment. 91
Irinotecan, its active metabolite SN-38, and topotecan, are chemotherapeutic camptothecin 92 derivatives (CPTs) acting as topoisomerase I (TOP1) poisons. 12 Human TOP1 is vital for 93 replication and transcription, as it relaxes DNA superhelical tension through phosphodiester bond 94 cleavage, strand rotation, and DNA resealing steps. 13 During the cleavage step, TOP1 covalently 95 attaches to the 3'-end of DNA with its catalytic tyrosine residue forming reversible DNA-TOP1 96 cleavage complexes (TOP1cc). Stabilization of the TOP1cc by TOP1 poisons generates 97 deleterious single-strand breaks (SSBs). 14 Collision between the replication fork and TOP1cc 98 produces DNA double-strand breaks (DSBs) and triggers cell death. 15 The lethal TOP1cc can be 99 trapped by endogenous DNA lesions and oxidative stress induced base modifications. 13, 16 100 Therefore, the irreversible TOP1cc must be countered by endogenous repair mechanism to 101 preserve genome integrity. 13, 17 Tyrosyl-DNA phosphodiesterase 1 (TDP1) liberates TOP1 peptide 6 from the 3' end of DNA by hydrolyzing the phosphotyrosyl-bond after proteasome-dependent 103 degradation of TOP1cc. 18 104 Human TDP1, a member of the phospholipase D superfamily, has two crucial catalytic residues, 105 H263 and H493. 19 A homozygous TDP1 H493R mutation is associated with familial 106 spinocerebellar ataxia with axonal neuropathy (SCAN1). 20,21 Lymphoblastoid cells derived from 107 SCAN1 patients are hypersensitive to CPTs resulting from a 25-fold reduction in TDP1 activity, 22 108 implying that TDP1 activity may suppress the effectiveness of CPTs. Moreover, TDP1 deficiency 109 in TDP1 knockdown cells confers enhanced cytotoxic response to CPT, whereas depletion of 110 TOP1 rescues cells from CPT-induced cell death. 23, 24 Additionally, phosphorylation of the TOP1 111 conserved-core domain elevates TOP1 activity, which in turn reduces cellular resistance to 112 CPT. 25, 26 The activity levels of both TOP1 and TDP1 may affect the anticancer efficacy of TOP1 113
poisons. 114
In this study, we measured the protein concentrations and activities of TOP1 and TDP1 in nine 115 GBM cell lines. Our results show that the TDP1/TOP1 activity ratio has a strong correlation with 116 irinotecan sensitivity. Furthermore, increased TDP1 activity by ectopic expression of TDP1 in 117 GBM cells conferred increased irinotecan resistance. 118 
Materials and Methods

119
Western blots 142
Protein expression levels were measured using Western blots as described in the Methods 143 Supplement. The primary and secondary antibodies are listed in Supplementary Table S1 . The 144 target protein images were obtained with C-DiGit Blot scanner (LI-COR) and analyzed by 145 ImageStudio (LI-COR). The TOP1 or TDP1 signal intensity for each WCE was first normalized 146 to actin signal to correct for loading, then divided by the NHA (fetal normal human astrocyte) 8 TOP1 or TDP1 signal intensity for comparison of relative TOP1 or TDP1 protein levels. GraphPad 148 Prism version 8.1 was used for the data analysis. The mean and standard deviations shown in bar 149 graphs were calculated based on at least 3 technical replicates. Degree of correlations between two 150 parameters tested was determined by using the Pearson correlation coefficient value (R) and 151 considered as significant for P < 0.05. Each entire set of experiments were repeated three times. The complete TDP1 coding sequence in wild-type (WT) and H263A mutant clones were verified 169 by DNA sequencing. 170
Transfection with TDP1 cDNA Clones 172
The transient transfection of GBM cell line H4, with WT-TDP1 and H263A-TDP1 clones were 173 performed with Lipofectamine 3000 (Invitrogen) according to its manufacturer's protocol. Briefly, 174 cells were seeded at a density of 1.8 × 10 5 cells/well in 35-mm dishes and cultured 24 h until 60% 175 confluence. DNA (500 ng) was mixed with Lipofectamine 3000 at a ratio of 1:2 (w/v) in 250 µL 176 of Opti-MEM Medium (Gibco) for 20 min at RT and added to cells. After further incubation for 177 24 h, WCEs were prepared using RIPA buffer as described above. Ten GBM tumors from patients (de-identified data shown in Supplementary Table S2 ) were used 194 to prepare WCEs. Frozen tumor tissues were transferred onto an ice-cooled 100-mm dish and 195 sliced into small pieces. The tumor segments were then weighed and RIPA/inhibitors lysis buffer 196 was added at a ratio of 1:10 (v/w). Samples were homogenized by Dounce Homogenizer and 197 rotated at 4°C for 2 h followed by centrifugation at 15000 x g for 15 min. Supernatant was kept in 198 aliquots at -80°C for further analysis. 
TDP1 activity measurement by gel-based assay 218
The P12Y oligonucleotide linked to tyrosine at the 3'-end (5'-HO-GAAAAAAGAGTT-PO4-Tyr-219 3', TopoGEN) was labeled at the 5'-end with 32 P. Recombinant human TDP1 was purified as 220 described. 28 The TOP1 and TDP1 protein expression levels in GBM cell lines were compared by Western blot 261 analysis of WCEs and normalized against NHA ( Fig. 1 ; Supplementary Table S4 ). The irinotecan 262 IC50 for individual cell line was measured using a cell-based assay to detect cell abundance 263
( Supplementary Table S3 ). No significant correlation (R=-0.254) was found between TOP1 264 protein levels and irinotecan IC50s ( Supplementary Table S9 ). A weak correlation between higher 265 TDP1 protein levels and increased IC50 values was observed (R=0.797, P=0.01; Supplementary 266 Table S9 ). These trends held across three distinct biological replicates ( Supplementary Fig. S1 , 267 Table S9 ) suggesting that TOP1 and TDP1 levels alone may not be highly predictive indicators of 268 irinotecan vulnerability. 269
270
TOP1 enzymatic activity in GBM cell lines does not correspond to the TOP1 protein level 271
Recombinant TOP1 was used to generate a linear standard curve for the increase in fraction of 272 DNA relaxed with increasing TOP1 activity ( Fig. 2A) . The TOP1 activity in serial dilutions of 273 each GBM WCE was assayed ( Fig. 2B ) and normalized against NHA ( Supplementary Table S5 ). 274
Results from additional biological replicates are shown in Supplementary Fig. S2 Table S9 ). These experiments indicate that TOP1 activity cannot predict irinotecan cytotoxicity in 279 GBM cell lines. 280
Measurement of TDP1 activity by gel-based and fluorescence-based assays 281
TDP1 can act as a broad-spectrum 3'-exonuclease to hydrolyze various phosphodiester linkages 282 at the 3'-ends of DNA. 19,31 A gel-based assay measured TDP1 activity with a 5'-32 P labeled 283 oligonucleotide with a 3'-tyrosine modification (P12Y) as substrate to yield P12 as the TDP1 284 reaction product in proportion to increasing amount of recombinant TDP1 (Fig. 2C) . In an 285 alternative fluorescence-based assay, a hairpin-structured oligonucleotide (Fig. 2D ) with a 5' 286 fluorophore and a 3'-BHQ1 modification was used as a substrate. 29 TDP1 removal of the quencher 287 at the 3'-end leads to an increase in fluorescence signal (ΔF). Activities in the GBM WCEs 288 measured in triplicates by the gel-based ( Fig. 2E ) or fluorescence-based assay (Fig. 2F) were 289 calculated based on the standard curve of recombinant TDP1 and normalized to TDP1 activity 290 level in NHA ( Supplementary Table S6 ). Results from additional replicates are shown in 291 Supplementary Fig. S3 . The TDP1 activities obtained from the gel-based and fluorescence-based 292 assays showed strong correlation (R = 0.943, Supplementary Fig. S3, panel D4) , demonstrating 293 their similar capabilities for measuring TDP1 activities in vitro. TDP1 activity levels assayed by 294 the two methods correlate only slightly with TDP1 protein levels measured by Western blot 295
( Supplementary Table S13 ) and irinotecan IC50 ( Supplementary Table S9 ). 296
TDP1/TOP1 activity ratio in GBM WCE is a strong predictor of irinotecan IC50 297
The lack of correlation between TOP1 and TDP1 protein expression ( Supplementary Table S7 ) 298 suggests that there is no overlapping pathway for regulating TOP1 and TDP1 levels. To further 299 identify more promising indicators for irinotecan sensitivity, we calculated the TDP1/TOP1 300 protein level ratio and the TDP1/TOP1 activity level ratio ( Supplementary Table S8 ). The 301 TDP1/TOP1 protein ratios (Fig. 3A) were weakly correlated with irinotecan IC50 (R=0.696, 302 P=0.037; Fig. 3B ). However, the TDP1/TOP1 activity ratios (Fig. 3C) were strongly correlated 303 15 with the irinotecan IC50 values (R=0.917, P=0.0005 for gel-based TDP1 assay; R=0.922, P=0.0004 304 for fluorescence-based TDP1 assay; Fig. 3D ). The results from two other sets of replicated 305 experiments also confirmed that the TDP1/TOP1 activity ratio is a strong predictor for irinotecan 306 IC50 ( Supplementary Table S9 ). 307
Increased resistance to irinotecan following transfection with recombinant TDP1 308
To follow up on the observed correlation between irinotecan sensitivity and TDP1/TOP1 activity 309 ratio, we elevated the TDP1 activity in H4 cell line by transfection with clones expressing WT-310 TDP1 or null activity mutant H263A-TDP1 19 and determined the effect on irinotecan IC50. 311
Overexpression of TDP1 and unchanged expression of TOP1 were confirmed by Western blotting 312 ( Fig. 4A ). Increase in TDP1 catalytic activity in the WCE from WT-TDP1 but not H263A-TDP1 313 was observed (Fig. 4B ) along with no change in TOP1 catalytic activity as expected. H4 cells 314 transfected with WT-TDP1 had significantly higher Irinotecan IC50 than H4 cells transfected with 315 H236A-TDP1 clone (Fig. 4C ). This result further supports the correlation between TDP1/TOP1 316 activity ratio and irinotecan IC50 for GBM. 317
Carboxylesterase 2 (CES2) activity in the GBM cell lines 318
Irinotecan is converted to the much more potent metabolite SN-38 by carboxylesterase isoform 319 CES2. 32 The CES2 activity present in the GBM cell lines were assayed and found to be comparable 320 ( Supplementary Fig. S5 ). This demonstrates that the relatively greater irinotecan resistance for 321 cell lines such as A172 and SNB75 was not due to lack of CES2 activity, and irinotecan sensitivity 322 of SNB19 was not due to relatively high level of CES2 being present in SNB19. Metabolic 323 conversion of irinotecan to SN-38 could be significant for irinotecan treatment efficacy in vivo. 33 324 Nevertheless, the observation made here that GBM cells with lower TDP1/TOP1 activity ratio 325 would be more sensitive to TOP1 poison is valid with the GBM CES2 activity data being taken 326 into consideration. 327
Variable levels of TDP1, TOP1 activities and TDP1/TOP1 activity ratio in GBM patient 328 tumor cell lysates 329 TOP1 and TDP1 expression as well as activity in the WCEs of ten GBM patient tumors were 330 measured (Fig. 5 ). The results ( Supplementary Table S10 ) showed that the GBM patient tumor 331
WCEs exhibited a greater range of TOP1 expression and activity than TDP1. The range of 332 TDP1/TOP1 protein and activity ratio is shown in Fig. 6 . It should be noted that tumor #62 is not 333 included in the graph for TDP1/TOP1 activity ratio in Fig. 6B because of the extremely low TOP1 334 activity in the WCE of this tumor specimen. The results show a better correlation between the 335 TOP1, TDP1 activity levels and TOP1, TDP1 protein levels for the GBM patient tumors than the 336 GBM cell line ( Supplementary Table S13 ). GBM patients with relatively high or low TDP1/TOP1 337 protein or activity ratio in the tumors could potentially be identified in the process of chemotherapy 338 treatment selection. 339 340 Discussion 341 GBM is a devastating disease with poor prognosis and lack of predictive biomarkers for 342 chemotherapy. 1 The prodrug irinotecan is converted to a topoisomerase I poison specifically to 343 stabilize the TOP1cc on chromosomal DNA. Irinotecan has been found in clinical trials to exhibit 344 modest and not consistently reproducible efficacy in the treatment of GBM. Therefore, our study 345 is aimed at evaluating the roles of TOP1 as target and the TOP1cc repair enzyme TDP1 on the 346 sensitivity of GBM to irinotecan in order to identify rational predictive biomarkers that may 347 contribute to improving the treatment outcomes. 348
349
Previous studies have shown that cytotoxicity of TOP1 poisons is associated with TOP1 and TDP1 350 protein expression as well as their catalytic activities. Infection of GBM cell lines with adenovirus 351 was found to increase TOP1 expression and activity, and enhance the antiglioma effect of 352 irinotecan. 34 A preliminary study on 9 clinical colorectal tumors indicated that the 3 samples with 353 the highest TOP1 expression and activity are from patients who responded to irinotecan. 35 A later 354 study on the roles of TDP1 and TOP1 in modulating colorectal cancer response to irinotecan 355 demonstrated that TDP1 overexpression or TOP1 depletion is protective while conversely TDP1 356 depletion leads to TOP1-dependent hypersensitivity to irinotecan, but there was no correlation 357 between inherent TDP1 or TOP1 protein levels alone and irinotecan sensitivity. 23 A study on 358 SCLC cell lines found that TDP1/TOP1 protein ratio is a better predictor than the individual TDP1 359 or TOP1 protein level. 36 360
361
In our study, we found that the TDP1/TOP1 activity ratio is superior to TDP1/TOP1 protein ratio 362 as a predictor for the response of GBM cell lines to irinotecan treatment as indicated by irinotecan 363
IC50s. This may be due to post-translational modification (PTM) of TOP1 and TDP1 proteins in 364 GBM. TOP1 phosphorylation increases TOP1 activities and cellular sensitivity to CPT. 26,37 O-365
GlcNAcylation can also elevate the activity of TOP1. 38 The PTMs could confer TOP1 activity 366 alterations and might account for the weaker correlation between TOP1 protein and its activity 367 levels in GBM cell lines. In contrast, the lesser influence of PTM on TDP1 activity might account 368 for the stronger correlation between TDP1 protein and its activity level. The z-scores for irinotecan, 369 camptothecin and topotecan are available in the CellMiner database for the 6 GBM cell lines 370 included in the NCI-60 panel ( Supplementary Table S11 ). 39, 40 The sensitivity z-scores for these 371 TOP1 inhibitors all show better correlation with our TDP1/TOP1 activity ratio than the 372 TDP1/TOP1 protein ratio or TDP1 protein and activity level alone ( Supplementary Table S12 ). 373
As expected, there is no correlation between TDP1/TOP1 activity ratio and sensitivity z-scores for 374 TOP2 inhibitors in CellMiner ( Supplementary Table S12 ). 375
376
The increase of irinotecan IC50 resulting from transfection of GBM H4 cell with recombinant 377 TDP1 clone is consistent with TDP1 activity being an important determinant of GBM sensitivity 378 to irinotecan. Combination therapy that targets both TOP1 and TDP1 has great potential to improve 379 the treatment outcomes of GBM. Therefore, the screening of TDP1 inhibitors is a promising venue 380 for developing new cancer therapies. 18,41,42 381 382 There are additional cellular factors that contribute to irinotecan treatment outcome. Degradation 383 of TOP1cc is necessary for sufficient exposure of the phosphodiester linkage to TDP1 hydrolysis. 13 384
Previous studies have shown that DNA damage-induced PTMs are associated with TDP1 N-385 terminal domain (NTD, residue 1-148). Phosphorylation, SUMOylation, and PARylation at NTD 386 stabilize TDP1 and promote TDP1 recruitment on DNA damage sites without interfering with its 387 activity. 43-46 388 389 Drug sensitivities are also determined in part by alternative repair pathways and epigenetic 390 modifications. PNKP and XRCC1 are required for SSB repair following the TDP1 repair 391 process. 13 RECQ1, Mus81-EME1, and XPF-ERCC1 could also provide resistance to CPTs on 392 either SSB or DSB repair pathways. [47] [48] [49] Perturbed histone acetylation stimulates faster access of 393 repair enzymes to the damaged sites and subsequently a higher resistance. 50 394 395 There is good correlation between TOP1 activity and TOP1 expression level in the ten GBM 396 patient tumors examined here (R=0.913, Supplementary Table S13 ), so the use of the TDP1/TOP1 397 protein ratio as a predictive biomarker for irinotecan sensitivity should be further examined along 398 with TDP1/TOP1 activity ratio for GBM patient tumors. 399
400
In summary, we demonstrate that the variation in TDP1/TOP1 activity ratio in GBM could be a 401 potential predictive biomarker for irinotecan treatment. 
